Latest summary of the recently released guidelines of the 8 hepatology departments, including one article!

This article summarizes the consensus of the relevant guidelines recently released at home and abroad in the field of liver disease for everyone to read and download!

The high number of people and the high risk of death from cirrhosis is one of the important components of the global burden of
disease.

In recent years, the role of terlipressin in cirrhosis-related complications has been gradually recognized
.

The Hepatobiliary Disease Group of the Gastroenterology Branch of the Chinese Medical Association and the Hepatopathy Professional Committee of the Chinese Research Hospital Association organized domestic experts in the fields of gastroenterology, liver disease, infectious diseases, surgery, and clinical pharmacy, and formulated a total of 10 practical guidance statements
on the clinical application of terlipressin in the complications of cirrhosis of the liver on the basis of a systematic review of the current evidence-based medical evidence and combined with the clinical experience of experts.

Link:

http://guide.

Recommended Reading:

What are the clinical applications of terlipressin in the complications of cirrhosis?| Guide consensus

Non-alcoholic fatty liver disease (NAFLD) is a widely popular clinicopathological syndrome that includes simple hepatic steatosis (NAFL) and nonalcoholic steatohepatitis (NASH), which in part eventually develops into cirrhosis and even evolves into hepatocellular carcinoma (HCC
).

The global prevalence of NAFLD in the Asian population is about 25%.


NAFLD is also a common chronic disease in the elderly, sarcopenia, obesity, type 2 diabetes mellitus (T2DM), hypercholesterolemia, hyperuricemia, fructose exposure, genetic background and Chinese medicine spleen deficiency is the susceptible factor of NAFLD in the elderly, its prevention and treatment involves digestion, endocrinology, cardiovascular, nutrition, exercise and other disciplines, perfect diagnosis and risk assessment, intervention and follow-up management requires multidisciplinary collaboration
.

Link:

http://guide.

Recommended Reading:

Management of non-alcoholic fatty liver disease in the elderly, the latest guidelines recommended at a glance!

Liver failure is a serious stage in the development of various liver diseases, with a high
case fatality rate.

Artificial liver can not only remove harmful substances from the patient's body, replenish essential substances, create opportunities for liver cell regeneration and liver function recovery, but also extend the patient's waiting time
for liver transplantation (LT).

Currently, in vitro albumin dialysis (ECAD) remains the primary artificial liver support system
used worldwide.

Albumin dialysis includes molecular adsorption recirculation systems (MARS), single-pass albumin dialysis and continuous albumin purification systems, of which MARS is the most studied and used system
worldwide.

Recently, the expert team provided guidance and recommendations on the application of artificial liver support in patients with liver failure, including the applicable population of albumin dialysis, the best time, technical and practical conditions, and monitoring methods
.

Link:

http://guide.
medlive.
cn/guideline/26715

Recommended Reading:

The application of artificial liver in liver failure, the international expert consensus released in 2022!

Acute kidney injury (AKI) is one
of the common complications in patients with cirrhosis.

Cirrhosis with AKI was associated
with a 7-fold increase in case fatality compared with patients without AKI.

Early diagnosis and treatment of AKI is critical to reducing case fatality and improving prognosis
.

In September 2022, the American College of Gastroenterology (AGA) updated its clinical practice recommendations for cirrhosis and AKI with 14 Best Practice Recommendations (BPAs).

Recommended Reading:

Evaluation and management of acute kidney injury, a common complication of cirrhosis, | Guide consensus

In China, liver cancer ranks among the 5th most common malignant tumors and the 2nd leading cause of
death.

Liver cancer, also referred to as "primary liver cancer", mainly includes a number of different pathological types
such as hepatocellular carcinoma and hepatobiliary duct cells.

The "Guidelines for the Integrated Diagnosis and Treatment of Tumors in China (CACA) - Liver Cancer Section" involves the epidemiology, screening, imaging examination, pathological assessment of liver cancer, as well as multidisciplinary integrated treatment methods such as surgical treatment, interventional therapy, systematic drug therapy, radiotherapy and traditional Chinese medicine treatment, taking into account the whole process of rehabilitation management
.

With regard to the tertiary prevention of liver cancer, the guidelines mainly address the following
.

Link:

http://guide.
medlive.
cn/guideline/26493

Recommended Reading:

The tertiary prevention of liver cancer, look at the guidelines for the integrated diagnosis and treatment of liver cancer in China!

Chinese group of liver cancer has a low survival rate and high mortality rate, how to effectively reduce the burden of liver cancer is still a major problem to be solved in the field of public health and chronic disease prevention and control in China, and the optimization of liver cancer population screening strategy is an important starting point and direction
worth continuous exploration.

The Chinese group liver cancer screening guidelines are entrusted by the Disease Prevention and Control Bureau of the National Health Commission, initiated by the National Cancer Center, and jointly developed by multidisciplinary experts to develop principles and methods in accordance with the guidelines recommended by the World Health Organization, integrate new domestic and foreign research evidence in the field of liver cancer population screening, take into account China's national conditions and practical experience, and present evidence-based recommendations for the screening population, screening technology, and monitoring programs in the process of liver cancer screening, in order to provide reference
for the specification of liver cancer screening practices in Chinese groups.

Link:

http://guide.
medlive.
cn/guideline/26678

Recommended Reading:

"Chinese Group Liver Cancer Screening Guidelines (2022, Beijing)" released!

In September 2022, the Italian Society of Hepatology (AISF) and several societies jointly published guidelines for benign liver lesions, which mainly cover the diagnosis and treatment
of hepatic substantial lesions, including hepatic hemangiomas, focal nodular hyperplasia, and hepatocellular adenomas.

Link:

http://guide.
medlive.
cn/guideline/26750

Recommended Reading:

Management of benign liver lesions: focal nodular hyperplasia and hepatocellular adenoma

Traditional Chinese medicine in the treatment of chronic hepatitis B has a wide clinical application basis in China and plays a very important role
.

A large number of clinical practices have proved that Chinese medicine can help improve the clinical symptoms of patients with chronic hepatitis B, promote the recovery of liver function, inhibit the process of liver fibrosis, and delay or stop the progression of
the disease.

Wuling capsules (pills) have been widely used in the treatment of chronic liver disease since their listing, but there is currently no consensus or guidelines developed by evidence-based medical methods to regulate their clinical application
in detail.

Therefore, on the basis of summarizing the experience of clinicians in medication, combined with the existing evidence-based evidence, the Hepatobiliary Disease Branch of the Chinese Association of Traditional Chinese Medicine took the lead in organizing Chinese and Western medicine hepatologists, methodological experts and pharmaceutical experts to jointly formulate this consensus, clarifying the indications, dosage, combined use and other issues of the clinical application of Wuling capsules (pills), as well as safety issues such as medication and contraindications for special populations, providing a reference for
the clinical application of Wuling capsules (pills).

Link:

http://guide.
medlive.
cn/guideline/26815